| Death |
|---|
| All-cause mortality: NPWT against Bogotá bag (1 trial) | 5/20 (25.0%) | 7/20 (35.0%) | RR 0.71 (0.27 to 1.88) | Cheng 2022 Meta-analysis / SR |
All-cause mortality, established deep sternal wound infection (34 retrospective cohorts, era-confounded) allocation by clinician, institution or era; no confounding adjustment | — | — | RR 0.46 (0.35 to 0.61); 34 trials | Liu 2024 Meta-analysis / SR |
All-cause mortality, obese or diabetic cardiac surgery patients (Prevena periods against standard dressing) OR 0.79 (0.52 to 1.20) as printed; cluster cross-over, not powered | 39/1022 (3.8%) | 57/1208 (4.7%) | RR 0.81 (0.54 to 1.20) | Scheier 2025 RCT |
| In-hospital death (modified ITT: one early death per arm excluded) | 0/83 (0.0%) | 1/82 (1.2%) | RR 0.33 (0.01 to 7.97) | Älgå 2020 RCT |
| Mortality, whole trial (3 of the 4 deaths in the ABThera arm) | 4/34 (11.8%) | — | — | Auer 2021 RCT |
In-hospital death, Fournier's gangrene (retrospective; printed p<0.05 does not reproduce, Fisher 0.17) adjusted OR 0.42 (0.18 to 0.95) on 19 events and 5 covariates | 10/64 (15.6%) | 9/31 (29.0%) | RR 0.54 (0.24 to 1.19) | Dogan 2026 Cohort / comparative |
| 30-day mortality, sternal NPWT | 2/176 (1.1%) | — | — | Sjögren 2010 Case series |
| Serious Deaths reported to the FDA with NPWT, 2007 to February 2011 (no denominator; most at home or in long-term care) | 12 reports | — | — | US 2011 HTA / regulatory |
| Bleeding |
|---|
| Serious Bleeding leading to transfusion, conflict-related extremity wounds | 32/81 (39.5%) | 24/78 (30.8%) | RR 1.28 (0.84 to 1.97) | Älgå 2020 RCT |
| 30-day coded bleeding, insured US children given NPWT (claims data) | 19/3184 (0.6%) children | — | — | Santosa 2019 Cohort / comparative |
| Serious Major bleeding (Yellin definition), sternal NPWT | 6/176 (3.4%) | — | — | Sjögren 2010 Case series |
Bleeding episodes, children with burns under NPWT upper 95% bound 11.7% | 0/29 (0.0%) children | — | — | Ren 2017 Case series |
| Serious Tibial artery erosion and haemorrhage on day 17 of NPWT (case report) | 1 report | — | — | White 2005 Case report |
| Serious Of those deaths, the ones with bleeding (vascular grafts, sternal and groin wounds, anticoagulation) | 9 reports | — | — | US 2011 HTA / regulatory |
| Providers who had seen bleeding with NPWT (FDA survey, 342 web respondents) | 22% of respondents | — | — | Kaufman-Rivi 2013 Survey / qualitative |
| Fistula |
|---|
| Serious Fistula: NPWT against Bogotá bag (1 trial) | 2/20 (10.0%) | 1/20 (5.0%) | RR 2.00 (0.20 to 20.33) | Cheng 2022 Meta-analysis / SR |
| Serious Enteric fistula: ABThera against Suprasorb CNP (both NPWT; ABThera in the NPWT column) | 4/17 (23.5%) | 0/17 (0.0%) | RR 9.00 (0.52 to 155.24) | Auer 2021 RCT |
| Intestinal fistulation after NPWT (secondary figure quoted from Rao) | 6/29 (20.7%) | — | — | Li 2014 Review / background |
| Ischaemia or tissue damage |
|---|
| Skin necrosis, closed incisions (fewer with NPWT) | — | — | RR 0.38 (0.18 to 0.80) | Patel 2026 Meta-analysis / SR |
Serious Right ventricular rupture during NPWT for deep sternal wound infection one per 522 NPWT-days | 4/176 (2.3%) | — | — | Sjögren 2010 Case series |
| Serious Right ventricular rupture under VAC after sternotomy (multi-institution case series; no denominator) | 5 reports | — | — | Sartipy 2006 Case series |
Serious Right ventricular rupture after 24 h at −120 mmHg over an unprotected heart, against a rigid barrier (porcine model) Pressure −120 mmHg | 3/8 (37.5%) animals | 0/8 (0.0%) | RR 7.00 (0.42 to 116.91) | Lindstedt 2011 Mechanism / in-vitro |
| Skin injury (blisters, maceration, dermatitis) |
|---|
Skin blistering, closed incisions (85 RCTs; abstract figures) NNH 18 as printed; full text not read | — | — | RR 4.51 (2.37 to 8.58) | Patel 2026 Meta-analysis / SR |
| Skin allergy under NPWT alone, pressure ulcers | 7/45 (15.6%) | — | — | Tian 2024 Cohort / comparative |
| Pain |
|---|
Pain on dressing removal, gauze-filled NPWT at −80 mmHg (no comparator; sponsor-authored) Pressure −80 mmHg | none at 80% of removals dressings | — | — | Hurd 2010 Case series |
| Pain or discomfort reported by inpatients on NPWT (qualitative interviews; 6 of 17 needed medication) | 12/17 (70.6%) | — | — | Miyanaga 2022 Survey / qualitative |
| Providers who had seen pain at dressing change (same survey) | 29% of respondents | — | — | Kaufman-Rivi 2013 Survey / qualitative |
| Retained foam or dressing |
|---|
| Serious Retained foam pieces in FDA injury reports, 2007 to 2009 | 32 reports | — | — | Hayes 2016 HTA / regulatory |
| Serious Retained foam causing persistent infection; found 1 month to 5 years later and not seen on X-ray | rate unknown (9 case reports and series) | — | — | Anagnostakos 2021 Review / background |
| Serious Foam accidentally left in the wound, of 24 MAUDE reports in the first half of 2006 | 8 reports | — | — | Medical 2006 HTA / regulatory |
| Device problems |
|---|
Device-related adverse events, closed incisions (85 RCTs; abstract figures) NNH 11 as printed | — | — | RR 11.87 (4.74 to 29.74) | Patel 2026 Meta-analysis / SR |
Device malfunction under closed-incision NPWT after panniculectomy (single-surgeon series) malfunction carried OR 3.3 (1.04 to 10.45) for any complication | 16/91 (17.6%) | — | — | Patel 2020 Case series |
| Pressure outside the usual range |
|---|
Adverse events at −75 against −125 mmHg (1 trial) Pressure −75 vs −125 mmHg; Certainty Very low | — | — | RR 1.50 (0.28 to 8.04); 1 trial, 40 patients | Liu 2018 Meta-analysis / SR |
A trial run at −600 mmHg (Buttenschön 2001), excluded by IQWiG; its pain rate was linked speculatively to the pressure Pressure −600 mmHg (−80 kPa) | 1 trial | — | — | Institute 2006 HTA / regulatory |
Fall in hand perfusion under a circumferential dressing, −400 against −125 mmHg (healthy volunteers, Cape Town) Pressure −400 vs −125 mmHg; no hand showed increased perfusion; same dataset as the Kairinos 2011 thesis | 40% vs 17% fall (both p < 0.0005) limbs | — | — | Kairinos 2009 Mechanism / in-vitro |
Perineal vacuum-sealing drainage run at −200 to −400 mmHg with continuous saline and intermittent hydrogen peroxide (no other source supports either) Pressure −200 to −400 mmHg | the whole NPWT arm | — | — | Li 2025 Cohort / comparative |
Transcutaneous oxygen under the foam at −125 mmHg fell by 84% to 6 mmHg in every diabetic foot tested Pressure −125 mmHg | 21/21 (100.0%) feet | — | — | Jung 2016 Case series |
Pressures used in maxillofacial and deep-neck vacuum-sealing drainage, with no safety data at these levels Pressure −300 to −450 mmHg (4 studies); −125 to −150 mmHg (1); one printed pressure value impossible | 4 of 6 studies above −300 mmHg | — | — | Freundlich 2026 Review / background |
| Other harms |
|---|
Cancer recurrence under NPWT after resection (6 observational studies) reassurance on 267 patients, not proof of safety | 11/118 (9.3%) | 17/149 (11.4%) | RR 0.82 (0.40 to 1.68) | Wang 2022 Meta-analysis / SR |
Adverse events, post-operative diabetic foot wounds (1 trial) Certainty Very low | — | — | RR 0.96 (0.72 to 1.28); 1 trial, 162 patients | Liu 2018 Meta-analysis / SR |
| Treatment-related adverse events, diabetic foot (3–4 RCTs) | — | — | RR 1.12 (0.66 to 1.89); 3 trials | Liu 2017 Meta-analysis / SR |
| Injury reports to the FDA with NPWT, same period | 174 reports | — | — | US 2011 HTA / regulatory |
| Adverse events with NPWT reported to the FDA (MAUDE), January 2000 to June 2006 | more than 100 reports | — | — | Medical 2006 HTA / regulatory |